New Multicenter Interspecialty Consensus on ADC Ocular Adverse Event Reporting to Improve Communication Between Eye Care Providers & Oncologists
Time: 11:45 am
day: Scientific Program Day One
Details:
- Understanding the ocular toxicities from ADCs and what constitutes a severe ocular adverse event
- Addressing the challenges of quantitatively assessing ocular toxicities with the current terminology criteria for adverse events (CTCAE) by mixing eye signs and symptoms
- Using our learnings to standardize the grading scales of ocular toxicities to better communicate eye findings to oncologists to create a safer ADC treatment plan with less toxicity
